NANOBIOSE | Linksium
Back to portfolio


Incorporated startups

Labs-on-a-chip for early drug assessment

profilePhoto   Jean-Philippe Gendre
Linksium Contact Jean-Philippe Gendre +33 (0)6 03 37 38 40
NANOBIOSE Damien Fleury, CEO +33 (0)4 79 26 67 57


  • Control of R&D costs
  • Impact of R&D strategy
  • Flexibility
  • Rapidity

Key words

  • Real-time & kinetic capture of secretion of biomarkers
  • Multiplexing
  • Nanodrugs
  • Immunotoxicology


  • UGA

Linksium Continuum

  • Incubation
  • Acceleration


  • Incorporated startups


90% of new drugs fail clinical trials on humans, which results in substantial financial losses for the pharmaceutical industry. This is mainly due to inadequate assessment during the early phases of R&D through the lack of predictive tests for effects on humans.


Based on microfluidics, the Nanobiose lab-on-a-chip integrates 3D cell culture technologies (imitating physiological conditions more effectively) and a removable biosensor that enables the multiplex analysis of biomarkers (up to 9) by measuring fluorescence.


  • Combination in a single experiment of 3D cell culture
  • Real-time capture of biomarkers secreted by the cells
  • Unique results (the kinetics of the biomarkers)
  • Significant saving in man-hours (< 50%)

State of progress

The POC was created with the support of BPI and thanks to a FrenchTech Emergence grant. Lab-on-a-chip prototypes and biosensors (5 cytokines tested) were produced and are currently used to develop a first application concerning a 3D model for the inflammation of human macrophages.


SecretCells® also enables researchers to assess the potential effects of their candidate drugs more rapidly and efficiently by creating a direct link between potential toxicity and efficacy.